Evidence map›Paper›PMID 32108909›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2020

Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.

Kasper Almholt, Jishu Wang, Jesper Pass, Gustav Røder, Søren B Padkjær, Josephine B Hebsgaard, Wenjuan Xia, Li Yang, Johan Forsell, Vibeke M Breinholt and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 2 countries.

Kasper AlmholtGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark. KAHL@novonordisk.com.ORCID 0000-0002-9250-514X
Jishu WangGlobal Research Technologies, Novo Nordisk China R&D, Beijing, China.
Jesper PassGlobal Research Technologies, Novo Nordisk A/S, Måløv, Denmark.
Gustav RøderGlobal Research Technologies, Novo Nordisk A/S, Måløv, Denmark.
Søren B PadkjærGlobal Research Technologies, Novo Nordisk A/S, Måløv, Denmark.
Josephine B HebsgaardGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Wenjuan XiaGlobal Research Technologies, Novo Nordisk China R&D, Beijing, China.
Li YangGlobal Research Technologies, Novo Nordisk China R&D, Beijing, China.
Johan ForsellGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Vibeke M BreinholtGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Peter ThygesenGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Henrik AgersøGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Mette LoftagerGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Pernille A UsherGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Novo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blocking the proteolytic capacity of urokinase-type plasminogen activator (uPA) with a monoclonal antibody (mAb) reduces arthritis progression in the collagen-induced mouse arthritis model to an extent that is on par with the effect of blocking tumor necrosis factor-alpha by etanercept. Seeking to develop a novel therapy for rheumatoid arthritis, a humanized mAb, NNC0266-0043, was selected for its dual inhibition of both the zymogen activation and the proteolytic capacity of human uPA. The antibody revealed nonlinear elimination kinetics in cynomolgus monkeys consistent with binding to and turnover of endogenous uPA. At a dose level of 20.6 mg kg

Indexed as

Drug DevelopmentAnimalsAntibodies, MonoclonalAntirheumatic AgentsArthritis, RheumatoidDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalHumansImmunohistochemistryMacaca fascicularisMacrophagesMiceMonocytesUrokinase-Type Plasminogen ActivatorAntibodies, MonoclonalAntirheumatic AgentsUrokinase-Type Plasminogen ActivatormAbPharmacodynamicsPharmacokineticsRheumatoid arthritisUrokinase

Identifiers

PMID32108909
OpenAlexW3008668736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.